Dassault Systèmes Lifts Guidance as Subscription Hits 50% of Recurring Revenue, but Life Sciences Is Still a Rebuild
Third-quarter 2026 earnings call and London investor event, October 28, 2026
A cleaner quarter, with the guide raised partly by M&A and FX
Dassault Systèmes reported Q3 revenue of EUR 1.552 billion, up 5%, at the top of its objectives. Operating margin rose 150 basis points to 31.6%, and EPS of EUR 0.32 grew 8% ex-FX. The company narrowed its full-year revenue growth range to 4% to 5% from 3% to 5%, or EUR 6.399 billion to EUR 6.459 billion. The midpoint rose by EUR 73 million. It also lifted its operating margin outlook to 32.5% to 32.7% from 32.2% to 32.6%, and EPS growth to 6% to 7% from 3% to 6%.
The raise needs context. Jefferies' Charles Brennan questioned whether it implied a quiet cut to Q4. CFO Rouven Bergmann pushed back and gave the bridge. Q3 beat the midpoint by about EUR 15 million, ArisGlobal adds EUR 30 million to EUR 35 million in Q4, and the remainder is currency. "It's not a downgrade of our organic perspective," Bergmann said. Q4 guidance calls for 5% to 8% growth including a 2-point ArisGlobal contribution, a 37.2% to 37.8% margin and EPS of EUR 0.42 to EUR 0.43. Kepler Cheuvreux's Laurent Daure noted that the Q4 midpoint looks softer than Q3 against easier comparisons. Management called the midpoint "very secured" but did not suggest the high end is likely. The organic raise is therefore modest, and most of the lift comes from the acquisition and FX.
Subscription crosses the halfway mark
The most important structural datapoint is that subscription now represents 50% of annual recurring revenue, up from 46% a year earlier. The share has risen about 1 point per quarter since Q3 2025. Total ARR reached EUR 4.505 billion, up 6%, and Bergmann said the subscription run rate is "moving towards mid-teens" growth. Maintenance growth has slowed from about 3% to roughly 0%, which accelerates the mix shift.
The gap between ARR growth of 6% and reported recurring revenue growth of 3% drew scrutiny. Bergmann attributed it to timing. ARR straight-lines 12 months of order entry, while multiyear subscriptions carry an upfront component in recognized revenue, which creates volatility. He expects recognized revenue to converge toward ARR as subscription grows. Investors should also note concentration: the top 15 deals accounted for about 80% of the net increase in subscription ARR. 3DEXPERIENCE grew 25%, cloud 14%, and 3DEXPERIENCE Cloud 46%.
Americas weak, Asia carrying the quarter
Regional performance was uneven. Asia grew 12%, led by China, where licenses grew 14% on a low base and the company cited aerospace momentum at COMAC and high-tech wins. Europe grew 9%, helped by renewals in the U.K. and France and partly offset by softness in Southern and Central Europe. The Americas fell 3% against a tough comparison, though management said High-Tech and Industrial Equipment are growing and described the region as more back-end loaded than others this year. Vertiv is the reference case for Gen 7 adoption in AI factory infrastructure. CEO Pascal Daloz framed the opportunity as "reduce the time to the first token," applying system-level engineering experience from nuclear to data centers.
Life Sciences: improving, not yet fixed
ArisGlobal, acquired for EUR 1.5 billion, closed in the second half of September and was immaterial to Q3. Dassault is folding MEDIDATA, BIOVIA and ArisGlobal into a single Life Sciences & Healthcare business under Dr. Ashwini Zenooz, a physician and technology entrepreneur. The group is building toward one AI-native platform on 3DEXPERIENCE. Daloz cited scale: 15 million patients in clinical trials, 60 million in real-world evidence, about half of global safety events, and 42,000 trials a year.
The numbers show a business still recovering. Life Sciences grew 1% after falling 4% in Q2. MEDIDATA was flat year on year, about 3 points better than the prior quarter, and management expects a further improvement of about 2 points in Q4 and a return to growth from then on. Platform agreements, with Worldwide Clinical Trials in Q1 and Everest in Q3, are the main lever. In response to Morgan Stanley's George Webb on sponsor mandates, Bergmann conceded the limits: "We're not shutting the door. We cannot do that." Clinical Data Studio works with any EDC, and the pitch rests on faster time to first patient in. Bergmann said 2027 guidance will be anchored on order entry and backlog, and that the headwinds from prior renewals are now more embedded in the base.
Agentic AI is still unmonetized, and 2027 is the test
Dassault has roughly 100 strategic customer partnerships working on the Virtual Companions (LEO, MARIE, AURA and LOUIS), including Volkswagen and Audi with Agile Robots. About 40% of the installed base is enabled, and a free discovery offer is meant to build usage ahead of 2027. In response to Bank of America's Frederic Boulan, Bergmann acknowledged the business is "more in a project mode" and that 2027 is the first year of client commitments tied to the Gen 7 revenue target set at the last Capital Markets Day. The model stays user-based, whether the user is a human or an agent, with usage measured in units of work and token consumption. Companion competencies cover about 50% of the portfolio and should exceed 80%. Management did not quantify the target.
On costs, CapEx was roughly EUR 100 million year to date, in line with last year, and normalized OpEx is growing at under 3%. Daloz said all 12,000 engineers use Cursor, and net hiring this year is slightly below 1,000, roughly half of what it would otherwise be.
Asked about AI labs moving into life sciences, including OpenAI's acquisition of Orchestra Bio, Daloz drew a line: "Orchestration is not science. You need both." He called the move "much more a topic for Veeva than for us because they are the workflows. We are the science." He added that open-weight models such as Nemotron, trained on proprietary data sets, can exceed frontier models on specific tasks. That is the basis of Dassault's positioning, but it remains an assertion until the monetization data arrives.
Consolidation: PTC and Schneider
On the proposed Schneider acquisition of PTC, Daloz said it "cleans the landscape" and leaves Dassault as the last pure-play in the space, with competitors absorbed into industrial conglomerates or EDA groups. He said he expects openings in the process industry, where Schneider is stronger than PTC, and against PTC's Windchill in fashion, where CENTRIC competes. He also suggested that PTC, as the last major U.S. player, leaves some sensitive U.S. domains more open to a European vendor. CENTRIC grew faster than the roughly 15% previously indicated, and SOLIDWORKS grew 6% or more, with double-digit unit growth and about one-third of new customers choosing cloud.
Cash conversion ahead of plan
Operating cash flow was EUR 1.567 billion year to date, up 20% ex-FX, with cash conversion at 111%. That funded the ArisGlobal deal and a EUR 0.9 billion bond repayment while leaving cash at EUR 3.814 billion and net cash at EUR 1.049 billion. Bergmann said the 2026 target of returning to 2024 levels is already exceeded, but he pointed to a 2027 cash conversion of 85% to 90%. That is a more measured outlook than the year-to-date figure suggests. The next catalyst is the Capital Markets Day in Paris on November 17.